Invention Grant
- Patent Title: Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
-
Application No.: US16652977Application Date: 2018-10-02
-
Publication No.: US11673962B2Publication Date: 2023-06-13
- Inventor: Cameron Durrant , Dale Chappell
- Applicant: HUMANIGEN, INC.
- Applicant Address: US NJ Short Hills
- Assignee: HUMANIGEN, INC.
- Current Assignee: HUMANIGEN, INC.
- Current Assignee Address: US NJ Short Hills
- Agency: Pearl Cohen Zedek Latzer Baratz LLP
- Agent Mark S. Cohen
- International Application: PCT/US2018/053933 2018.10.02
- International Announcement: WO2019/070680A 2019.04.11
- Date entered country: 2020-04-01
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/24 ; A61K39/395 ; C07K14/535 ; A61P43/00 ; A61K39/00 ; A61K35/17 ; A61K38/00
Abstract:
Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGMCSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.
Information query
